>99% OF INVASIVE MenB STRAINS CONTAIN GENES FOR AT LEAST 1 BEXSERO COMPONENT"scrollbars=yes, resizable=yes, width=400, height=400,top=500, left=500"3,*

BEXSERO is the only MenB vaccine that combines 4 different antigenic components—fHbp, NadA, NHBA, and PorA P1.4—each of which targets a different mechanism related to MenB survival and disease development."scrollbars=yes, resizable=yes, width=400, height=400,top=500, left=500"4,5,*

fHbp=factor H binding protein; NadA=Neisserial adhesin A; NHBA=Neisserial Heparin Binding Antigen; PorA P1.4 present in Outer Membrane Vesicles (OMV).

* The susceptibility of serogroup B meningococci to complement-mediated antibody-dependent killing following vaccination with BEXSERO is dependent on both the antigenic similarity of the bacterial and vaccine antigens, as well as the amount of antigen expressed on the surface of the invading meningococci."scrollbars=yes, resizable=yes, width=400, height=400,top=500, left=500"1

 

 

MenB strains can express varying amounts of surface protein."scrollbars=yes, resizable=yes, width=400, height=400,top=500, left=500"6,7

The majority of invasive MenB strains contain genes for more than 1 BEXSERO component, potentially providing multiple targets for vaccine-induced antibodies."scrollbars=yes, resizable=yes, width=400, height=400,top=500, left=500"3

 

BEXSERO offers the potential to protect against invasive MenB strains, even when the expression of 1 component is low or antigenically different."scrollbars=yes, resizable=yes, width=400, height=400,top=500, left=500"6,7

Vaccination with BEXSERO may not provide protection against all meningococcal serogroup B strains.

INDICATION

BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals 10 through 25 years of age.

Approval of BEXSERO is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed.

IMPORTANT SAFETY INFORMATION FOR BEXSERO

  • BEXSERO is contraindicated in cases of hypersensitivity, including severe allergic reaction, to any component of the vaccine, or after a previous dose of BEXSERO
  • Appropriate observation and medical treatment should always be readily available in case of an anaphylactic event following the administration of the vaccine
  • The tip caps of the prefilled syringes contain natural rubber latex, which may cause allergic reactions in latex-sensitive individuals
  • Syncope (fainting) can occur in association with administration of BEXSERO. Ensure procedures are in place to avoid injury from falling associated with syncope
  • The most common solicited adverse reactions observed in clinical trials were pain at the injection site (≥83%), myalgia (≥48%), erythema (≥45%), fatigue (≥35%), headache (≥33%), induration (≥28%), nausea (≥18%), and arthralgia (≥13%)
  • Vaccination with BEXSERO may not provide protection against all meningococcal serogroup B strains
  • Vaccination with BEXSERO may not result in protection in all vaccine recipients

Please see full Prescribing Information for BEXSERO.